SELLAS Life Sciences' GPS Combo Therapy Shows Overall Survival Of 18 Months In Pretreated Ovarian Cancer Patients

SELLAS Life Sciences Group Inc SLS announced confirmatory topline data from the final analysis of results from its Phase 1/2 trial of galinpepimut-S (GPS).
The trial assessed GPS in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) for WT1(+) relapsed or refractory platinum-resistant advanced metastatic ovarian cancer.
Median Overall Survival (OS) was 18.4 months compared to 13.8 months in a checkpoint inhibitor single-agent study.
Also Read: SELLAS Life Sciences Touts Encouraging Preclinical Data For Candidate For Aggressive Form Of Prostate Cancer.
Median Progression-Free Survival (PFS) was 12 weeks compared to eight weeks.
The trial's overall response rate (ORR) is 6.3%, with a disease control rate (DCR.
In a checkpoint inhibitor single-agent study in a similar platinum-resistant ovarian cancer patient population treated with a checkpoint inhibitor alone, the observed DCR was 37.2%.
The safety profile of GPS in combination with pembrolizumab was similar to pembrolizumab alone, with the only addition of low-grade, rapidly resolving local reactions at the GPS injection site.
In May, the company announced data from a clinical trial of GPS plus Bristol-Myers Squibb Co's BMY Opdivo (nivolumab), showing a median overall survival (OS) of 40.9 weeks (9.4 months).
Price Action: SLS shares are down 5.34% at $4.68 on the last check Thursday.